Clinical trial Recruiting at 1 site Interventional Ages 18 to 89

Can fluoroscopy plus TTE guidance improve leadless pacemaker placement accuracy

Official title: Multimodality Location Prediction Accuracy of Leadless Pacemaker Positioning (MAP)

Run by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · NCT07908927 · Data updated 2026-11-12

This study tests whether using transthoracic echocardiography (TTE) during leadless pacemaker placement improves accuracy and safety compared with standard fluoroscopy.

Quick facts

Study typeInterventional
Ages18 Years to 89 Years
SexAll
Enrollment20 (estimated)
SponsorAllegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Academic / other
Locations1 site (Pittsburgh, Pennsylvania)
StatusRecruiting
StartedMay 13, 2026
Main results expectedMarch 31, 2028
Study endsMay 31, 2028
Registry record updatedNovember 2, 2026
Trial IDNCT07908927 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults age 18-89 undergoing implantation of a new Micra VR or AV2 leadless pacemaker.

Probably not a fit

Patients with contraindications to iodinated contrast or who do not undergo CTA verification may not benefit from this approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults undergoing a new Micra VR or AV2 leadless pacemaker implantation will have their implant site predicted by the implanter and two independent electrophysiologists using fluoroscopy. Each participant will then have a TTE and three independent assessments of the implant site, followed within 48 hours by a contrast-enhanced CTA which serves as the reference standard to determine the true location. The primary endpoint compares the predicted implant site from the implanting electrophysiologist, fluoroscopy, and TTE against the CTA gold standard. Interventions focus on cardiac imaging using TTE or CTA to inform implant placement. The study aims to assess whether TTE-guided implantation can improve placement accuracy and safety, particularly regarding the risk of right ventricular perforation.

Why it matters

Potential benefit: If successful, TTE-guided implantation could improve leadless pacemaker placement accuracy and reduce complication risks.

How similar studies have gone: Prior work has explored imaging-guided device placement, but this study prospectively compares fluoroscopy, TTE, and CTA against a CTA gold standard for leadless pacemakers.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male and female patients aged 18-89, inclusive.
* All patients undergoing implant of a new Micra VR or AV2 leadless pacemaker.

Exclusion Criteria:

* Women who are pregnant or breastfeeding
* Existing device implant
* Breast or Pectoral Implants
* Patients with a GFR less than 45, unless the patient is on dialysis (in which case, may be included)
* Known allergy to iodinated contrast.
* Any other condition or finding that, in the opinion of the investigator, would contraindicate participation.

Where it's running

  • Allegheny Health Network
    Pittsburgh, Pennsylvania, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.